- Home
- CNR vs TFX Comparison
CNR vs TFX Comparison
Compare CNR & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNR | TFX |
|---|---|---|
| Founded | 1864 | 1943 |
| Country | United States | United States |
| Employees | 4850 | N/A |
| Industry | Coal Mining | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.6B |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | CNR | TFX |
|---|---|---|
| Price | $104.73 | $119.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $111.50 | ★ $138.75 |
| AVG Volume (30 Days) | ★ 1.1M | 713.3K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | 0.36% | ★ 1.18% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,992,713,000.00 |
| Revenue This Year | $7.04 | $16.02 |
| Revenue Next Year | $6.48 | $5.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $58.19 | $100.18 |
| 52 Week High | $114.80 | $141.91 |
Technical Indicators
Market Signals| Indicator | CNR | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 53.82 | 65.04 |
| Support Level | $85.03 | $116.71 |
| Resistance Level | $113.57 | $123.74 |
| Average True Range (ATR) | 5.36 | 3.30 |
| MACD | 0.52 | 0.99 |
| Stochastic Oscillator | 40.74 | 98.29 |
Price Performance
Historical ComparisonAbout CNR Core Natural Resources Inc.
Core Natural Resources Inc is a producer and exporter of metallurgical and thermal coal. The company owns and operates longwall mining operations in the nation and export terminals on the Eastern seaboard. The activities of the company involves mining of thermal coal, power generation, and other related activities.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.